China Pledges RMB 800 Million For Cataract Surgeries, Bringing Ophthalmic Market Potential Into Focus
This article was originally published in PharmAsia News
With a large aging population, China’s ophthalmic market is poised to see growth, and companies with mixed product portfolios will be the biggest winners, analysts say.
You may also be interested in...
In China, A Province's Drastic Price Cut Model Is Being Modified To Fit A Nationwide System: A Look At The Anhui Model
SHANGHAI - Since China's healthcare reforms started in 2009, the central government has been encouraging local government to pilot different tender models for essential drugs to reduce public medical expenses. Anhui Province's tender system became a successful example by reducing essential drug prices an average 40-50% last year, and now the central government is implementing a single supplier procurement system, the so-called Anhui model, nationwide
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.